Literature DB >> 8077618

Atrial natriuretic peptide and cyclic guanosine monophosphate plasma concentrations in patients with thyrotoxicosis and atrial fibrillation. Effect of short-term methimazole therapy.

S Czekalski1, K Widecka, J Gozdzik, K Ciechanowski, B Krzyzanowska-Swiniarska, E Gromniak, M Gruszczynska.   

Abstract

Plasma immunoreactive atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP), serum thyroxine (T4), triiodothyronine (T3), and thyrotropin (TSH) concentrations were measured in 11 patients with thyrotoxicosis and atrial fibrillation (group 1), in 5 patients with thyrotoxicosis and sinus cardiac rhythm (group 2) and in 8 healthy subjects in comparable age. Patients with thyrotoxicosis were studied before and after treatment with methimazole (3 x 20 mg daily) during 10 days. During treatment sinus cardiac rhythm returned in 6 patients with initial fibrillation (group 1a) while 5 patients still presented atrial fibrillation at the end of the study (group 1b). All patients from group 2 maintained a sinus cardiac rhythm throughout the study. Median plasma concentrations of ANP and cGMP before treatment in patients from group 1 were higher: 43.8 pmol/l and 11.0 nmol/l, respectively than in patients from group 2: 20.0 pmol/l (p < 0.005) and 6.5 nmol/l (p < 0.01), respectively. In all groups of patients methimazole treatment resulted in a significant decrease of plasma ANP and cGMP concentrations in parallel to a reduction of serum T3 and T4 levels. After therapy, plasma ANP and cGMP levels in patients from group 1a were not significantly different from those in patients from group 2, while in patients from group 1b remained slightly elevated. Presented results suggest that atrial fibrillation in patients with thyrotoxicosis represents an important factor augmenting plasma ANP and cGMP levels, in addition to the stimulatory effect exerted by thyroid hormones. However, the marked reduction of serum thyroid hormones produced by short-term methimazole treatment in patients with thyrotoxicosis was associated with parallel decrease of plasma ANP and cGMP levels toward normal values. Therefore, the influence of thyroid hormones on plasma ANP and cGMP concentrations seems relatively more important than the effect of atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077618     DOI: 10.1007/BF03348996

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  HEMODYNAMIC CONSEQUENCES OF ATRIAL FIBRILLATION AT CONSTANT VENTRICULAR RATES.

Authors:  N S SKINNER; J H MITCHELL; A G WALLACE; S J SARNOFF
Journal:  Am J Med       Date:  1964-03       Impact factor: 4.965

2.  Circulating atrial natriuretic peptides in hyperthyroidism and hypothyroidism.

Authors:  M Kohno; K Murakawa; K Yasunari; Y Nishizawa; H Morii; T Takeda
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

3.  Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor.

Authors:  B S Edwards; R S Zimmerman; T R Schwab; D M Heublein; J C Burnett
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

4.  Increased circulating atrial natriuretic peptide in patients with thyrotoxicosis.

Authors:  M Kohno; T Matsuura; K Yasunari; M Yasuda; T Takeda; Y Nishizawa; H Morii
Journal:  Arch Intern Med       Date:  1986-10

5.  Plasma atrial natriuretic factor and cyclic GMP in mitral stenosis treated by balloon valvulotomy. Effect of atrial fibrillation.

Authors:  J C Dussaule; A Vahanian; P L Michel; I Soullier; S Czekalski; J Acar; R Ardaillou
Journal:  Circulation       Date:  1988-08       Impact factor: 29.690

6.  Plasma levels of atrial natriuretic peptide in hyperthyroidism.

Authors:  A S Woolf; P J Moult
Journal:  Clin Endocrinol (Oxf)       Date:  1987-12       Impact factor: 3.478

7.  Role of cardiac parasympathetic dysfunction in atrial natriuretic peptide response to volume changes in patients with chronic renal failure.

Authors:  W Pruszczynski; B Viron; S Czekalski; F Mignon; R Ardaillou
Journal:  Miner Electrolyte Metab       Date:  1987

8.  Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia.

Authors:  D Roy; F Paillard; D Cassidy; M G Bourassa; J Gutkowska; J Genest; M Cantin
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

9.  Role of right and left atrial dimensions for release of atrial natriuretic peptide in left-sided valvular heart disease and idiopathic dilated cardiomyopathy.

Authors:  M Haass; R Dietz; T A Fischer; R E Lang; W Kübler
Journal:  Am J Cardiol       Date:  1988-10-01       Impact factor: 2.778

10.  Plasma atrial natriuretic peptide in states of altered thyroid function.

Authors:  T Yamaji; M Ishibashi; F Takaku; F Sato; K Kamoi
Journal:  Endocrinol Jpn       Date:  1988-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.